ORLADEYO Treatment: Real-world Evidence on Reduced HAE Attack Rates for Patients with Normal C1-Inhibitor
Sunday, 2 June 2024, 05:12
ORLADEYO Treatment for HAE Patients
The latest real-world evidence from BioCryst reveals a substantial reduction in attack rates among Hereditary Angioedema (HAE) patients with normal C1-Inhibitor after starting ORLADEYO treatment.
Potential Therapeutic Breakthrough
BioCryst's findings highlight the efficacy of ORLADEYO (berotralstat) in managing HAE symptoms and improving patient outcomes, offering a promising therapeutic option for those with normal C1-Inhibitor facing HAE attacks.
- Significant reduction in attack rates observed
- Improvement in patient outcomes demonstrated
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.